CD86 and B-cell non-Hodgkin lymphoma: To further assess the anti-tumor efficacy of CTLA4-T cells against primary tumors, we developed B cell lymphoma PDX mouse models by using primary tumor tissues with high CD80 and CD86 expression (Figure 2D).